Cordyceps Sunshine Biotech Holdings Ratios (2020-2025) | RAJAF

Ratios Dec2020 Dec2021 Dec2022 Sep2023 Dec2023 Dec2024 Dec2025
Profitability
Gross Margin (Quarter) 90.22%
EBT Margin (Quarter) 26.44%
EBIT Margin (Quarter) 38.18%
EBITDA Margin (Quarter) 212.77%
Operating Margin (Quarter) 38.18%
FCF Margin (Quarter) -980.58%
Efficiency
Inventory Average (Quarter) 0.02M0.02M
Assets Average (Quarter) 3.04M2.68M1.95M2.57M3.99M4.64M
Equity Average (Quarter) -0.14M-0.61M-0.57M-0.17M-0.26M-0.46M
Invested Capital (Quarter) 1.27M1.30M-0.54M-0.18M-0.15M0.07M-0.07M
Leverage & Solvency
Debt to Equity (Quarter) -132.65-7.20-0.87-2.26-2.84-1.19-0.87
Debt Ratio (Quarter) 0.600.610.390.230.130.100.10
Equity Ratio (Quarter) 0.00-0.08-0.45-0.10-0.05-0.08-0.11
Valuation
Enterprise Value (Quarter) -294.00-0.10M-0.01M-0.02M-0.02M-0.04M-0.00M
Return Ratios
Return on Assets (Quarter) 0.00%0.00%0.00%
Return on Equity (Quarter) 0.01%0.04%0.01%